If you take Ozempic, Wegovy, Mounjaro, or Zepbound, or you are simply trying to make sense of GLP-1s (glucagon-like peptide-1) and GIPs (glucose-dependent insulinotropic polypeptide), you may have seen a recent Medscape article asking whether GIP really adds any benefit in type 2 diabetes. It is a fair scientific question. The problem is that the headline makes the answer sound much clearer than it is.

The study behind the article, published in The Lancet Diabetes & Endocrinology, tested whether adding the natural hormone GIP to semaglutide improved blood sugar in adults with type 2 diabetes. The researchers did not find the large added improvement they had designed the study to detect.

That is useful information. It does not prove that the GIP part of tirzepatide is useless.

They did not actually study tirzepatide

Semaglutide mainly activates the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors.

But the researchers did not give participants tirzepatide. They gave some participants semaglutide while continuously infusing natural GIP under the skin.

Those treatments are not the same thing.

Tirzepatide is one engineered molecule with its own receptor activity, signaling, and long half-life. Research in human pancreatic islets has shown that blocking the GIP receptor reduces tirzepatide-stimulated insulin secretion, supporting the idea that tirzepatide uses both receptors.

So semaglutide plus natural GIP is not “homemade tirzepatide.” It is a different experiment.

A small study and a short window

The trial enrolled 61 people, divided among four groups. That left only 15 or 16 people in each group. Ten participants, about one in six, stopped early. The authors acknowledged that one comparison could not support firm conclusions because of the dropouts. Small studies can be valuable, but they also mean greater uncertainty.

Participants first had an eight-week run-in with semaglutide or placebo. Semaglutide was given at 0.25 mg weekly for four weeks and then 0.5 mg weekly for four weeks. The six-week GIP infusion then began while semaglutide stayed at 0.5 mg.

That makes this useful as a short-term physiology study. It is much less useful for judging the long-term weight and glucose effects of tirzepatide, which develop over months.

What do the statistics mean in normal English?

The key comparison (semaglutide plus GIP versus semaglutide alone) showed almost no difference in average glucose. But the confidence interval ranged from about 15 mg/dL lower to 17 mg/dL higher.

Think of a confidence interval as the study admitting, “We are not sure where the true answer sits inside this range.” That is a wide range. It means the study could not rule out a smaller benefit or a smaller harm. The trial was also powered to detect an extra glucose reduction of about 27 mg/dL, a large added effect.

So the strongest conclusion is not “GIP does nothing.” It is: “Adding this dose of natural GIP to 0.5 mg semaglutide for six weeks did not produce the large extra glucose reduction the researchers were looking for.” Those statements sound similar, but scientifically they are very different.

What does the rest of the research say?

A Nature Metabolism study using human pancreatic islets found that blocking the GIP receptor consistently reduced tirzepatide-stimulated insulin secretion. That does not prove how much GIP contributes to weight loss or long-term A1C reduction in people, but it argues against the simple idea that tirzepatide is merely a GLP-1 drug wearing a GIP name tag.

Then there are the large clinical trials. SURPASS-2 followed 1,879 adults with type 2 diabetes for 40 weeks. Tirzepatide lowered A1C more than semaglutide 1 mg at every tirzepatide dose tested and also produced greater weight loss.

SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity without diabetes. After 72 weeks, average weight loss was about 20 percent with tirzepatide versus about 14 percent with semaglutide.

These studies do not prove that GIP alone explains tirzepatide’s advantage. The benefit may come from the interaction of both receptors, unique receptor signaling, or mechanisms we have not fully worked out.

Biology rarely reads the instruction manual.

But these trials establish something important: Tirzepatide’s clinical effectiveness is not in doubt simply because a small native-GIP experiment was negative. The American Diabetes Association’s 2026 Standards of Care add useful perspective. The ADA identifies tirzepatide and semaglutide as the currently available agents with the highest efficacy for both glucose lowering and weight loss.

Conflicts of interest deserve context, not accusations

Readers should also know who funded research and what relationships investigators have. The Lancet study reports funding from Novo Nordisk, the manufacturer of semaglutide. Several investigators disclosed relationships with Novo Nordisk. Some investigators also have financial or founder relationships with Antag Therapeutics, a company developing medicines that block the GIP receptor.

That information is relevant because this debate centers on whether activating or blocking GIP is helpful. But a financial relationship does not prove that a study is wrong or that anyone acted improperly. Industry funding is common in drug research. For balance, the major tirzepatide trials were funded by Eli Lilly, the company that developed tirzepatide. Conflicts are disclosed so readers can understand the context and then judge the methods, statistics, and conclusions for themselves.

So what should patients take away?

This was a worthwhile mechanistic study. It showed that six weeks of natural GIP added to 0.5 mg semaglutide did not produce the large additional glucose reduction the investigators had expected.

It did not test tirzepatide. It did not prove that GIP adds nothing to tirzepatide. And it does not overturn large randomized trials showing that tirzepatide is highly effective for lowering A1C and body weight.

Science should challenge our assumptions. That is how medicine improves.

But before a small study changes how we think about a medication supported by thousands of patients in large clinical trials, we should ask one simple question: What did the researchers actually test? In this case, the answer was natural GIP plus semaglutide, not tirzepatide. That difference may sound small.

Scientifically, it is anything but.

Jeffrey Laman is a family physician.